Nothing Special   »   [go: up one dir, main page]

BRPI0514269A - compostos heterocìclicos como agentes farmacêuticos - Google Patents

compostos heterocìclicos como agentes farmacêuticos

Info

Publication number
BRPI0514269A
BRPI0514269A BRPI0514269-5A BRPI0514269A BRPI0514269A BR PI0514269 A BRPI0514269 A BR PI0514269A BR PI0514269 A BRPI0514269 A BR PI0514269A BR PI0514269 A BRPI0514269 A BR PI0514269A
Authority
BR
Brazil
Prior art keywords
pharmaceutical agents
heterocyclic compounds
compounds
receptor activity
compositions
Prior art date
Application number
BRPI0514269-5A
Other languages
English (en)
Inventor
Richard Martin
Brenton T Flatt
Jeffrey D Kahl
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of BRPI0514269A publication Critical patent/BRPI0514269A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTOS HETEROCìCLICOS COMO AGENTES FARMACêUTICOS A presente invenção refere-se a compostos, composições e métodos para modular a atividade de receptores são fornecidos. Em particular, compostos e composições são fornecidos para modular a atividade de receptores e para o tratamento, prevenção, ou melhora de um ou mais sintomas da doença ou distúrbio direta ou indiretamente relacionados à atividade dos receptores.
BRPI0514269-5A 2004-08-10 2005-08-09 compostos heterocìclicos como agentes farmacêuticos BRPI0514269A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60023904P 2004-08-10 2004-08-10
PCT/US2005/028357 WO2006020680A2 (en) 2004-08-10 2005-08-09 Heterocyclic compounds as pharmaceutical agents

Publications (1)

Publication Number Publication Date
BRPI0514269A true BRPI0514269A (pt) 2008-06-10

Family

ID=35908114

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0514269-5A BRPI0514269A (pt) 2004-08-10 2005-08-09 compostos heterocìclicos como agentes farmacêuticos

Country Status (9)

Country Link
US (1) US7902237B2 (pt)
EP (1) EP1776112A4 (pt)
JP (1) JP2008509912A (pt)
CN (1) CN101010078A (pt)
AU (1) AU2005272916A1 (pt)
BR (1) BRPI0514269A (pt)
CA (1) CA2574279A1 (pt)
MX (1) MX2007001539A (pt)
WO (1) WO2006020680A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009501776A (ja) * 2005-07-21 2009-01-22 ベタゲノン・エイビー 遊離脂肪酸に起因した障害におけるチアゾール誘導体およびアナログの使用
DE102007003524A1 (de) * 2007-01-19 2008-09-04 MEDICE Arzneimittel Pütter GmbH & Co. KG Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose
WO2008090356A1 (en) * 2007-01-25 2008-07-31 Betagenon Ab Thiazolidinone derivatives useful in the treatment of cancer and disorders caused by excess adiposity
CN101274918A (zh) * 2007-03-30 2008-10-01 中国科学院上海药物研究所 一类取代五元杂环化合物,其制备方法和医学用途
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
WO2012106581A1 (en) * 2011-02-03 2012-08-09 The University Of Chicago Fxr inhibitor, bile acid sequestrant as combination therapy for cholesterol reduction
NZ719360A (en) * 2012-06-19 2017-08-25 Intercept Pharmaceuticals Inc Preparation, uses and solid forms of obeticholic acid
CA2920017C (en) 2013-08-01 2021-11-23 Frank J. Gonzalez Inhibitors of the farnesoid x receptor and uses in medicine
RS61540B1 (sr) 2013-09-11 2021-04-29 Inst Nat Sante Rech Med Postupci i farmaceutske kompozicije za tretiranje infekcije hepatitis b virusa
US10300048B2 (en) 2014-05-28 2019-05-28 Universitat Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
EP2952188A1 (en) * 2014-06-03 2015-12-09 Universität Bern Thiazolidinones as cellular anandamide uptake inhibitors and their use in the treatment of psychiatric or neurological disorders and inflammation, in particular neuroinflammation
AU2016238523A1 (en) 2015-03-26 2017-11-09 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
TW201741307A (zh) * 2016-02-22 2017-12-01 艾洛斯生物製藥公司 Ｆｘｒ調節劑及其使用方法
CN110944635A (zh) 2017-03-30 2020-03-31 国家医疗保健研究所 用于减少附加体病毒的持久性和表达的方法和药物组合物
WO2019032902A1 (en) * 2017-08-10 2019-02-14 The Texas A & M University System NR4A1 LIGANDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE523919A (pt) * 1952-10-31
US2719162A (en) * 1954-03-29 1955-09-27 Eastman Kodak Co 5-(3-hydroxybenzylidene)-3-phenyl-2-phenylimino-4-thiazolidone and process
US3097100A (en) * 1960-01-25 1963-07-09 Eastman Kodak Co Thiazolidones as light stabilizers for plastic compositions
BE608790A (fr) 1960-10-08 1962-04-03 Kalle Ag Matériel photosensible.
US3314794A (en) 1964-05-13 1967-04-18 Eastman Kodak Co Ultraviolet absorbers
FR1548312A (pt) * 1967-06-06 1968-12-06
US5198454A (en) * 1991-12-03 1993-03-30 Texas A&M University System Use of OB-104 to treat ocular inflammation
JPH06128234A (ja) 1992-10-19 1994-05-10 Fuji Photo Film Co Ltd 不斉炭素原子を有する化合物およびそれからなる非線形光学材料
JP3871354B2 (ja) * 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
US6353006B1 (en) * 1999-01-14 2002-03-05 Bayer Corporation Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
WO2003060078A2 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors

Also Published As

Publication number Publication date
WO2006020680A2 (en) 2006-02-23
CA2574279A1 (en) 2006-02-23
CN101010078A (zh) 2007-08-01
US20080132519A1 (en) 2008-06-05
EP1776112A4 (en) 2009-11-25
MX2007001539A (es) 2007-04-23
AU2005272916A1 (en) 2006-02-23
EP1776112A2 (en) 2007-04-25
US7902237B2 (en) 2011-03-08
JP2008509912A (ja) 2008-04-03
WO2006020680A3 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
BRPI0513677A (pt) derivados de pirrol com agentes farmacêuticos
BRPI0417260A (pt) derivados de azepinoindol como agentes farmacêuticos
BRPI0412262A (pt) derivados de azepina como agentes farmacêuticos
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
BRPI0514269A (pt) compostos heterocìclicos como agentes farmacêuticos
ATE547420T1 (de) Azepinoindol und pyridoindolderivate als pharmazeutische mittel
BR112012018500A2 (pt) alguns inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de uso destas
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200800100A1 (ru) Соединения азаиндазола и способы применения
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
NO20084712L (no) Nye farmasoytiske forbindelser
BRPI0610090A2 (pt) terapia de combinaÇço compreendendo diaril urÉias para tratar doenÇas
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
DE602006013191D1 (de) Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
TW200733961A (en) Diaryl urea for treating pulmonary hypertension
BRPI0512352A (pt) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
BRPI0516883A (pt) compostos e métodos para modulação da atividade de trombopoietina
UA108073C2 (ru) 2,5-дизамещенные арилсульфонамидные антагонисты ccr3
BRPI0507626A (pt) compostos e composiçoes como moduladores de lxr

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.